JP2011500837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500837A5 JP2011500837A5 JP2010531255A JP2010531255A JP2011500837A5 JP 2011500837 A5 JP2011500837 A5 JP 2011500837A5 JP 2010531255 A JP2010531255 A JP 2010531255A JP 2010531255 A JP2010531255 A JP 2010531255A JP 2011500837 A5 JP2011500837 A5 JP 2011500837A5
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- cell
- ppm
- membrane
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012530 fluid Substances 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 20
- 230000004068 intracellular signaling Effects 0.000 claims description 16
- 210000004379 membrane Anatomy 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 210000000170 cell membrane Anatomy 0.000 claims description 10
- 210000002390 cell membrane structure Anatomy 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 8
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 8
- 102000034353 G alpha subunit Human genes 0.000 claims description 6
- 108091006099 G alpha subunit Proteins 0.000 claims description 6
- 108090000862 Ion Channels Proteins 0.000 claims description 6
- 102000004310 Ion Channels Human genes 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 102000027257 transmembrane receptors Human genes 0.000 claims description 6
- 108091008578 transmembrane receptors Proteins 0.000 claims description 6
- 102000030621 adenylate cyclase Human genes 0.000 claims description 4
- 108060000200 adenylate cyclase Proteins 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 230000021164 cell adhesion Effects 0.000 claims description 4
- 230000008602 contraction Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 208000012239 Developmental disease Diseases 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 208000017701 Endocrine disease Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000012641 Pigmentation disease Diseases 0.000 claims description 2
- 206010036590 Premature baby Diseases 0.000 claims description 2
- 102000014384 Type C Phospholipases Human genes 0.000 claims description 2
- 108010079194 Type C Phospholipases Proteins 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000014461 bone development Effects 0.000 claims description 2
- 230000008468 bone growth Effects 0.000 claims description 2
- 230000005821 brain abnormality Effects 0.000 claims description 2
- 230000007885 bronchoconstriction Effects 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 210000001047 desmosome Anatomy 0.000 claims description 2
- 229910001882 dioxygen Inorganic materials 0.000 claims description 2
- 210000003560 epithelium corneal Anatomy 0.000 claims description 2
- 210000003976 gap junction Anatomy 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 102000006240 membrane receptors Human genes 0.000 claims description 2
- 108020004084 membrane receptors Proteins 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 210000001578 tight junction Anatomy 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000031146 intracellular signal transduction Effects 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000006078 pseudohypoparathyroidism Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98272007P | 2007-10-25 | 2007-10-25 | |
| US98271907P | 2007-10-25 | 2007-10-25 | |
| US60/982,719 | 2007-10-25 | ||
| USPCT/US2007/082581 | 2007-10-25 | ||
| USPCT/US2007/082580 | 2007-10-25 | ||
| PCT/US2007/082578 WO2008052143A2 (en) | 2006-10-25 | 2007-10-25 | Mixing device and output fluids of same |
| US60/982,720 | 2007-10-25 | ||
| PCT/US2007/082580 WO2008052145A2 (en) | 2006-10-25 | 2007-10-25 | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| PCT/US2007/082581 WO2008115290A2 (en) | 2006-10-25 | 2007-10-25 | Methods of wound care and treatment |
| USPCT/US2007/082578 | 2007-10-25 | ||
| US4834008P | 2008-04-28 | 2008-04-28 | |
| US4840408P | 2008-04-28 | 2008-04-28 | |
| US4833208P | 2008-04-28 | 2008-04-28 | |
| US4834708P | 2008-04-28 | 2008-04-28 | |
| US61/048,404 | 2008-04-28 | ||
| US61/048,340 | 2008-04-28 | ||
| US61/048,347 | 2008-04-28 | ||
| US61/048,332 | 2008-04-28 | ||
| PCT/US2008/081021 WO2009055614A1 (en) | 2007-10-25 | 2008-10-23 | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014121357A Division JP2014205693A (ja) | 2007-10-25 | 2014-06-12 | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500837A JP2011500837A (ja) | 2011-01-06 |
| JP2011500837A5 true JP2011500837A5 (https=) | 2011-12-08 |
| JP5613565B2 JP5613565B2 (ja) | 2014-10-22 |
Family
ID=42261767
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531255A Expired - Fee Related JP5613565B2 (ja) | 2007-10-25 | 2008-10-23 | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
| JP2010531276A Expired - Fee Related JP5911197B2 (ja) | 2007-10-25 | 2008-10-24 | 嚢胞性線維症を治療するための組成物および方法 |
| JP2010531290A Active JP5869763B2 (ja) | 2007-10-25 | 2008-10-24 | 炎症を治療するための組成物および方法 |
| JP2014117564A Pending JP2014193915A (ja) | 2007-10-25 | 2014-06-06 | 嚢胞性線維症を治療するための組成物および方法 |
| JP2014121357A Withdrawn JP2014205693A (ja) | 2007-10-25 | 2014-06-12 | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
| JP2014121350A Withdrawn JP2014169328A (ja) | 2007-10-25 | 2014-06-12 | 炎症を治療するための組成物および方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531276A Expired - Fee Related JP5911197B2 (ja) | 2007-10-25 | 2008-10-24 | 嚢胞性線維症を治療するための組成物および方法 |
| JP2010531290A Active JP5869763B2 (ja) | 2007-10-25 | 2008-10-24 | 炎症を治療するための組成物および方法 |
| JP2014117564A Pending JP2014193915A (ja) | 2007-10-25 | 2014-06-06 | 嚢胞性線維症を治療するための組成物および方法 |
| JP2014121357A Withdrawn JP2014205693A (ja) | 2007-10-25 | 2014-06-12 | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
| JP2014121350A Withdrawn JP2014169328A (ja) | 2007-10-25 | 2014-06-12 | 炎症を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP2215260A4 (https=) |
| JP (6) | JP5613565B2 (https=) |
| CN (5) | CN101910412B (https=) |
| AU (3) | AU2008316794B2 (https=) |
| CA (3) | CA2703672A1 (https=) |
| IL (3) | IL205319A (https=) |
| MX (3) | MX2010004563A (https=) |
| WO (1) | WO2009055614A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| AU2007308838B2 (en) | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| MX2010004549A (es) * | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos bacteriostáticos o bactericidas. |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| AU2009241365B2 (en) * | 2008-04-28 | 2015-01-22 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US8980325B2 (en) | 2008-05-01 | 2015-03-17 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| CA2741336A1 (en) * | 2008-10-22 | 2010-04-29 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| AU2010241736B2 (en) * | 2009-04-27 | 2016-01-28 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| BR112012028540A2 (pt) * | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
| KR20130050952A (ko) | 2010-06-16 | 2013-05-16 | 브루스 챈들러 메이 | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
| JP2013533320A (ja) | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
| KR20130100126A (ko) * | 2010-08-13 | 2013-09-09 | 레발레시오 코퍼레이션 | 심혈관 질환을 치료하기 위한 조성물 및 방법 |
| US20120263764A1 (en) * | 2011-04-13 | 2012-10-18 | Revalesio Corporation | Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
| JP6368459B2 (ja) * | 2012-06-14 | 2018-08-01 | 松本 高明 | 点眼液の製造方法 |
| RU2015134423A (ru) | 2013-03-13 | 2017-04-26 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
| MX382776B (es) | 2013-03-13 | 2025-03-13 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. |
| WO2014164285A2 (en) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| WO2016044095A1 (en) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| CN106943593A (zh) * | 2017-03-24 | 2017-07-14 | 浙江中医药大学 | 抗tslp抗体在制备防治慢性瘙痒药物中的应用 |
| CA3064050A1 (en) * | 2017-05-23 | 2018-11-29 | Biovite Australia Pty Ltd. | Extracts from arthrospira and uses thereof |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| CN112305153B (zh) * | 2020-10-16 | 2022-09-23 | 中石化石油工程技术服务有限公司 | 一种膨润土含量的自动分析检测仪及其检测方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518483D0 (en) * | 1995-09-09 | 1995-11-08 | Thompson Royce Ltd | Lighting control systems |
| US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
| US6386751B1 (en) * | 1997-10-24 | 2002-05-14 | Diffusion Dynamics, Inc. | Diffuser/emulsifier |
| EP1100811B1 (en) * | 1998-07-28 | 2007-07-04 | The Regents Of The University Of California | Nucleic acids encoding a g-protein coupled receptor involved in sensory transduction |
| EP1237578A4 (en) * | 1999-10-26 | 2004-10-27 | Bio Hydration Res Lab Inc | MICRO-AGGREGATED LIQUIDS AND METHODS OF MAKING AND USING SAME |
| US20060198901A9 (en) * | 1999-10-26 | 2006-09-07 | Holloway William D Jr | Drugs, bio-affecting and body treating compositions |
| WO2001042451A2 (en) * | 1999-12-08 | 2001-06-14 | Genset | FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS |
| US7255881B2 (en) * | 2000-07-27 | 2007-08-14 | Nucryst Pharmaceuticals Corp. | Metal-containing materials |
| WO2002024222A2 (en) * | 2000-09-20 | 2002-03-28 | The Cleveland Clinic Foundation | Ligands for g protein coupled receptors and methods of using them |
| US20040235732A1 (en) * | 2000-11-03 | 2004-11-25 | Qun-Yong Zhou | Method for modulating angiogenesis using prokineticin receptor antagonists |
| EP1357920B1 (en) * | 2001-02-01 | 2007-09-05 | Hydron Technologies Inc. | Compositions and method of tissue superoxygenation |
| GB0118383D0 (en) * | 2001-07-27 | 2001-09-19 | Pharmagene Lab Ltd | Therapeutic methods |
| DE10227818A1 (de) * | 2002-06-21 | 2004-01-08 | Pakdaman, Abolghassem, Prof. Dr.med. | Gasanreicherungsmodule |
| AU2002321678A1 (en) * | 2002-09-09 | 2004-03-29 | Boros Béla | Oxygen-enriched water, treated within a magnetic field and heavy water |
| US7790762B2 (en) * | 2002-10-31 | 2010-09-07 | National Jewish Health | Compounds and methods for thiol-containing compound efflux and cancer treatment |
| US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| ATE500234T1 (de) * | 2003-11-10 | 2011-03-15 | Merck Sharp & Dohme | Substituierte trialzole als blocker des natriumkanals |
| US20050139808A1 (en) * | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
| US20060073212A1 (en) * | 2004-04-22 | 2006-04-06 | Palmer Craig R | Method of treating respiratory disorders and airway inflammation |
| AU2005329764B2 (en) * | 2005-03-28 | 2010-08-12 | Dabur Pharma Ltd. | Stable pharmaceutical compositions of platinum (II) antitumour agents |
| EP1901749B1 (en) * | 2005-05-18 | 2016-08-03 | Raptor Pharmaceuticals Inc. | Aerosolized fluoroquinolones and uses thereof |
| GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| US8597689B2 (en) * | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| AU2007308838B2 (en) * | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| JP5491185B2 (ja) * | 2006-10-25 | 2014-05-14 | リバルシオ コーポレイション | 傷のケアおよび処置の方法 |
| MX2010004549A (es) * | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos bacteriostáticos o bactericidas. |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
-
2008
- 2008-10-23 EP EP08842968A patent/EP2215260A4/en not_active Withdrawn
- 2008-10-23 JP JP2010531255A patent/JP5613565B2/ja not_active Expired - Fee Related
- 2008-10-23 WO PCT/US2008/081021 patent/WO2009055614A1/en not_active Ceased
- 2008-10-23 AU AU2008316794A patent/AU2008316794B2/en not_active Ceased
- 2008-10-23 MX MX2010004563A patent/MX2010004563A/es active IP Right Grant
- 2008-10-23 CA CA2703672A patent/CA2703672A1/en not_active Abandoned
- 2008-10-23 CN CN200880122893XA patent/CN101910412B/zh not_active Expired - Fee Related
- 2008-10-24 CN CN201510111837.8A patent/CN104771758A/zh active Pending
- 2008-10-24 JP JP2010531276A patent/JP5911197B2/ja not_active Expired - Fee Related
- 2008-10-24 EP EP08841991A patent/EP2224924A4/en not_active Withdrawn
- 2008-10-24 AU AU2008316623A patent/AU2008316623B2/en active Active
- 2008-10-24 CN CN201410108422.0A patent/CN103933567A/zh active Pending
- 2008-10-24 CA CA2703739A patent/CA2703739A1/en not_active Abandoned
- 2008-10-24 CA CA2703754A patent/CA2703754C/en active Active
- 2008-10-24 AU AU2008316663A patent/AU2008316663B2/en not_active Ceased
- 2008-10-24 CN CN200880122816.4A patent/CN101909623B/zh not_active Expired - Fee Related
- 2008-10-24 CN CN200880122817.9A patent/CN101909648B/zh active Active
- 2008-10-24 MX MX2010004564A patent/MX2010004564A/es active IP Right Grant
- 2008-10-24 MX MX2010004554A patent/MX2010004554A/es active IP Right Grant
- 2008-10-24 EP EP08841701.9A patent/EP2214707B1/en active Active
- 2008-10-24 JP JP2010531290A patent/JP5869763B2/ja active Active
-
2010
- 2010-04-25 IL IL205319A patent/IL205319A/en not_active IP Right Cessation
- 2010-04-25 IL IL205317A patent/IL205317A/en not_active IP Right Cessation
- 2010-04-25 IL IL205318A patent/IL205318A/en active IP Right Grant
-
2014
- 2014-06-06 JP JP2014117564A patent/JP2014193915A/ja active Pending
- 2014-06-12 JP JP2014121357A patent/JP2014205693A/ja not_active Withdrawn
- 2014-06-12 JP JP2014121350A patent/JP2014169328A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500837A5 (https=) | ||
| Ng et al. | Making sense with thyroid hormone—the role of T3 in auditory development | |
| Kogawa et al. | Osteoclastic metabolism of 25 (OH)-vitamin D3: a potential mechanism for optimization of bone resorption | |
| Matsumoto et al. | Claudin 2 deficiency reduces bile flow and increases susceptibility to cholesterol gallstone disease in mice | |
| Naur et al. | Ionotropic glutamate-like receptor δ2 binds D-serine and glycine | |
| Zhang et al. | Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule | |
| Manzke et al. | Serotonin targets inhibitory synapses to induce modulation of network functions | |
| Fontella et al. | Repeated restraint stress alters hippocampal glutamate uptake and release in the rat | |
| Gnatenco et al. | Functional expression of TREK-2 K+ channel in cultured rat brain astrocytes | |
| MX2011011333A (es) | Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. | |
| Parrock et al. | KCNJ10 mutations display differential sensitivity to heteromerisation with KCNJ16 | |
| MX337862B (es) | Composiciones y métodos para el tratamiento de la esclerosis multiple. | |
| Brugeaud et al. | Control of hair cell excitability by vestibular primary sensory neurons | |
| AU2003269354A1 (en) | Methods for promoting dopaminergic neuronal development by using NG4A-subfamily and Wnt-ligands | |
| Hascup et al. | Resting glutamate levels and rapid glutamate transients in the prefrontal cortex of the Flinders Sensitive Line rat: a genetic rodent model of depression | |
| Onaka et al. | Facilitative role of endogenous oxytocin in noradrenaline release in the rat supraoptic nucleus | |
| Yoshihara et al. | Astrocytic Ca2+ responses in the spinal dorsal horn by noxious stimuli to the skin | |
| Gulati et al. | A preclinical evaluation of a programmable CNT membrane device for transdermal nicotine delivery in hairless Guinea pigs | |
| Brandner | Pores in the epidermis: aquaporins and tight junctions | |
| Negri | Role of claudins in renal calcium handling | |
| Stitt et al. | Scratch and sniff: the dynamic duo | |
| Liu et al. | Glycine receptor-mediated inhibition of medial prefrontal cortical pyramidal cells | |
| Zheng et al. | Investigating lipid–lipid and lipid–protein interactions in model membranes by ToF-SIMS | |
| Vega et al. | Acid-sensing ionic-channel functional expression in the vestibular endorgans | |
| BR112021008395A2 (pt) | Composições de aminoácidos e métodos para tratamento da fibrose cística |